Clinical Trials, Therapy Area

Phase I Study of Bromodomain Inhibitor OTX015 in Patients with Lymphoma or Multiple Myeloma

By Oncology Therapeutic Development (OTD)

This white paper describes the methods and findings of a dose-escalation, open-label, pharmacokinetic, Phase I study of bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma.

This first-in-class small molecule inhibitor specifically binds to bromodomain motifs BRD2, BRD3 and BRD4 of bromodomain and extraterminal (BET) proteins, inhibiting them from binding to acetylated histones, which occurs preferentially at super-enhancer regions that control oncogene expression.

Download this free white paper to find out more.

Enter your details below to view the free white paper

By downloading this whitepaper, you acknowledge that GlobalData may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.